Tackling immune-mediated disease with CAR Tregs
Here, Jason Fontenot, Chief Scientific Officer of Sangamo Therapeutics, discusses…
Here, Jason Fontenot, Chief Scientific Officer of Sangamo Therapeutics, discusses with EPR’s Hannah Balfour how the industry is developing chimeric antigen receptor (CAR) T regulatory cells (Tregs) as a potentially paradigm-shifting therapeutic option for conditions driven by the immune system, such as autoimmunity and transplant rejection.